MedTrace Logo

Chia Seed Impact on Postprandial Glycemia and Appetite in Overweight Adults

NCT07797049 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-09-01

No results posted yet for this study

Summary

Overweight and obesity affect nearly 2.5 billion adults worldwide and increase cardiometabolic risk. Postprandial glucose excursions are influenced by diet and inactivity and predict metabolic disorders, while South Asians, particularly Pakistanis, are more vulnerable due to genetic and lifestyle factors and processed diets. This study evaluates the impact of chia seed (Salvia hispanica L.) ingestion on postprandial glycemia and appetite in overweight adults, supporting UN Sustainable Development Goal 3 (Good Health and Well-being).

A randomized controlled crossover trial will be conducted among 30 overweight adults (BMI 25-29.9 kg/m²), aged 18-40 years. Participants will undergo control and intervention phases separated by a 14-day washout. The control beverage will contain 50 g glucose in 250 mL water, while the intervention beverage will contain the same beverage supplemented with 30 g chia seeds. Glucose response will be assessed using incremental area under the curve (iAUC) by the trapezoidal method, with appetite response also evaluated. Data will be analyzed using SPSS version 25; baseline characteristics will be presented as mean ± SD, and between-group differences will be assessed using a linear mixed model at p \< 0.05. Chia seed ingestion is expected to reduce postprandial blood glucose and improve appetite control.

Conditions

  • Overweight Adults
  • Postprandial Glycemia
  • Appetite Response

Interventions

DIETARY_SUPPLEMENT

Chia Seed (Salvia hispanica L.) Beverage

Participants will consume a standardized beverage containing 50 g glucose dissolved in 250 mL water, without chia seeds or any other fiber-containing ingredient. This beverage will serve as the control condition for comparison with the chia seed-supplemented glucose beverage.

Sponsors & Collaborators

  • University of Veterinary and Animal Sciences, Lahore - Pakistan

    lead OTHER

Principal Investigators

  • Dr. Qaisar Raza · University of Veterinary and Animal Sciences 54000 Lahore

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-28
Primary Completion
2026-09-28
Completion
2026-10-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07797049 on ClinicalTrials.gov